Therapixel
therapixel.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Therapixel is a French medical imaging company founded in 2013 and based on the Cote d'Azur. Its MammoScreen software applies deep learning to mammograms to help radiologists detect breast cancer earlier. The product is approved in Europe and cleared by the United States Food and Drug Administration.
News
Second FDA okay for Therapixel's AI-based mammography tool
France's Therapixel has secured a second FDA approval for MammoScreen, its artificial intelligence-powered software for detecting cancerous lesions in mammogram images. MammoScreen was approved last year for use alongside conventional digital 2D mammograp
Read more
Report
MammoScreen Breast AI Adopted by Mayo Clinic for Radiology Use
Chicago/Paris, April 22, 2025 - Therapixel, the developer of MammoScreen, an AI-based breast cancer screening software, announces that Mayo Clinic has procured licenses for the use of MammoScreen across its radiology departments. The software provides rad
Read more
Report
Therapixel and Onsite Women's Health Announce Partnership to Deploy MammoScreen AI for Enhanced Breast Cancer Detection Across National Provider Network
PARIS and CHICAGO and NASHVILLE, April 3th, 2025 -Therapixel, creators of MammoScreen, a leading artificial intelligence (AI) solution for breast cancer screening, today announced a strategic partnership with Onsite Women's Health, one of the nation's lar
Read more
Report
Pro access
Upgrade to see all 16 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.